{{Rsnum
|rsid=1143671
|Gene=SLC15A2
|Chromosome=3
|position=121928439
|Orientation=plus
|GMAF=0.4908
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC15A2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 26.5 | 54.0 | 19.5
| HCB | 5.1 | 40.9 | 54.0
| JPT | 4.4 | 36.3 | 59.3
| YRI | 21.8 | 51.7 | 26.5
| ASW | 38.6 | 43.9 | 17.5
| CHB | 5.1 | 40.9 | 54.0
| CHD | 6.4 | 40.4 | 53.2
| GIH | 48.5 | 39.6 | 11.9
| LWK | 32.7 | 47.3 | 20.0
| MEX | 62.1 | 29.3 | 8.6
| MKK | 30.1 | 38.5 | 31.4
| TSI | 42.2 | 49.0 | 8.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1143671
|Name_s=SLC15A2: S409P
|Gene_s=SLC15A2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=PEPT2*1 (350L-409P-509R) showed lower K m for glycyl-sarcosine as compared with PEPT2*2 (350F- 409S-509K) in transfected cells.
|Drugs=glycyl-sarcosine
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111599
}}

{{PMID Auto
|PMID=18698231
|Title=Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
|OA=1
}}

{{GET Evidence
|gene=SLC15A2
|aa_change=Pro409Ser
|aa_change_short=P409S
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1143671
|overall_frequency_n=5048
|overall_frequency_d=10758
|overall_frequency=0.469232
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=50
|n_articles=0
|n_articles_annotated=0
|nblosum100=3
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}